Paper20101022
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
Stein R and 7 others. Blood, 2010. Cited by 39 papers, by iCite.
Cite this record
ConductScience Library. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Papers, record 20101022. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20101022
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| B-Lymphocytes | Major topic |
| Cytotoxins | Major topic |
| Extracellular Signal-Regulated MAP Kinases | Major topic |
| HLA-DR Antigens | Major topic |
| Hematologic Neoplasms | Major topic |
| MAP Kinase Kinase 4 | Major topic |
| MAP Kinase Signaling System | Major topic |
| Animals | |
| Antigens, CD | |
| Cell Line, Tumor | |
| Drug Screening Assays, Antitumor | |
| Enzyme Activation | |
| Female | |
| Humans | |
| Mice | |
| Mice, SCID |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P01 CA103985 | NCI NIH HHS | United States | P01CA103985 | PubMed and NIH |
| 1P01-CA103985 | NCI NIH HHS | United States | P01CA103985 | PubMed and NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | Background | ClinicalTrials.gov | |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 20576816 | HLA-DR meets ERK. | https://conductscience.org/library/papers/20576816 |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11975981 | HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. | Hum Immunol | 2002 | https://conductscience.org/library/papers/11975981 | PubMed |
| 2 | 19022808 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. | Ann Rheum Dis | 2008 | https://conductscience.org/library/papers/19022808 | PubMed |
| 3 | 9660836 | Identification of a novel inhibitor of mitogen-activated protein kinase kinase. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9660836 | PubMed |
| 4 | 18799057 | Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. | Clin Exp Rheumatol | 2008 | https://conductscience.org/library/papers/18799057 | PubMed |
| 5 | 10557099 | From receptors to stress-activated MAP kinases. | Oncogene | 1999 | https://conductscience.org/library/papers/10557099 | PubMed |
| 6 | 19011506 | A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. | Medicine (Baltimore) | 2008 | https://conductscience.org/library/papers/19011506 | PubMed |
| 7 | 9731049 | Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. | Blood | 1998 | https://conductscience.org/library/papers/9731049 | PubMed |
| 8 | 19000095 | Anti-CD20 treatment in primary Sjögren's syndrome. | Scand J Immunol | 2008 | https://conductscience.org/library/papers/19000095 | PubMed |
| 9 | 15174097 | Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. | J Cell Physiol | 2004 | https://conductscience.org/library/papers/15174097 | PubMed |
| 10 | 12101408 | Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. | Nat Med | 2002 | https://conductscience.org/library/papers/12101408 | PubMed |
| 11 | 12153000 | In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. | Leuk Lymphoma | 2002 | https://conductscience.org/library/papers/12153000 | PubMed |
| 12 | 17875789 | CD74: a new candidate target for the immunotherapy of B-cell neoplasms. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17875789 | PubMed |
| 13 | 12576316 | Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). | Blood | 2003 | https://conductscience.org/library/papers/12576316 | PubMed |
| 14 | 11675350 | Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. | Blood | 2001 | https://conductscience.org/library/papers/11675350 | PubMed |
| 15 | 15226177 | From the bench to the bedside: ways to improve rituximab efficacy. | Blood | 2004 | https://conductscience.org/library/papers/15226177 | PubMed |
| 16 | 6606682 | Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. | J Immunol Methods | 1983 | https://conductscience.org/library/papers/6606682 | PubMed |
| 17 | 15297317 | Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. | Blood | 2004 | https://conductscience.org/library/papers/15297317 | PubMed |
| 18 | 11843813 | Complement activation plays a key role in the side-effects of rituximab treatment. | Br J Haematol | 2001 | https://conductscience.org/library/papers/11843813 | PubMed |
| 19 | 17071489 | A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. | Leuk Lymphoma | 2006 | https://conductscience.org/library/papers/17071489 | PubMed |
| 20 | 9841871 | Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades. | Biochem J | 1998 | https://conductscience.org/library/papers/9841871 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42864501 | Combined rituximab and magnesium acetyl taurate therapy attenuates neurodegeneration via ERK/c-JNK/P38MAPK signaling modulation in methylmercury-induced amyotrophic lateral sclerosis-like neurotoxicity. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42864501 | PubMed |
| 41514561 | Fab Antibody Fragments to Dog Leukocyte Antigen DR (DLA-DR) Directly Suppress Canine Lymphoma Cell Line Growth In Vitro and in Murine Xenotransplant Model. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514561 | PubMed |
| 35563109 | Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35563109 | PubMed |
| 32934776 | Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers. | Oncotarget | 2020 | https://conductscience.org/library/papers/32934776 | PubMed |
| 31561563 | An Antibody Specific for the Dog Leukocyte Antigen DR (DLA-DR) and Its Novel Methotrexate Conjugate Inhibit the Growth of Canine B Cell Lymphoma. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31561563 | PubMed |
| 31443721 | ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. | Cell Commun Signal | 2019 | https://conductscience.org/library/papers/31443721 | PubMed |
| 29715484 | B cell MHC class II signaling: A story of life and death. | Hum Immunol | 2019 | https://conductscience.org/library/papers/29715484 | PubMed |
| 29475988 | HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. | J Immunol | 2018 | https://conductscience.org/library/papers/29475988 | PubMed |
| 29022919 | DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway. | Cell Death Dis | 2017 | https://conductscience.org/library/papers/29022919 | PubMed |
| 28932638 | The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28932638 | PubMed |
| 27203743 | The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. | Oncotarget | 2016 | https://conductscience.org/library/papers/27203743 | PubMed |
| 27128741 | Gamma-Tocotrienol Modulates Radiation-Induced MicroRNA Expression in Mouse Spleen. | Radiat Res | 2016 | https://conductscience.org/library/papers/27128741 | PubMed |
| 27119356 | Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. | Oncotarget | 2016 | https://conductscience.org/library/papers/27119356 | PubMed |
| 26694167 | ASK1/JNK-mediated TAp63 activation controls the cell survival signal of baicalein-treated EBV-transformed B cells. | Mol Cell Biochem | 2016 | https://conductscience.org/library/papers/26694167 | PubMed |
| 25865044 | Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. | Oncotarget | 2015 | https://conductscience.org/library/papers/25865044 | PubMed |
| 25773122 | A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. | J Cancer Res Clin Oncol | 2015 | https://conductscience.org/library/papers/25773122 | PubMed |
| 25639873 | The tumor microenvironment shapes hallmarks of mature B-cell malignancies. | Oncogene | 2015 | https://conductscience.org/library/papers/25639873 | PubMed |
| 24670986 | Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab. | MAbs | 2014 | https://conductscience.org/library/papers/24670986 | PubMed |
| 24037527 | The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. | Oncogene | 2014 | https://conductscience.org/library/papers/24037527 | PubMed |
| 23090290 | Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. | Cancer Immunol Immunother | 2012 | https://conductscience.org/library/papers/23090290 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD22 | 933 | PubTator's text mining | https://conductscience.org/library/genes/933 | NCBI Gene |
| CD74 | 972 | PubTator's text mining | https://conductscience.org/library/genes/972 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
| MAP2K4 | 6416 | PubTator's text mining | https://conductscience.org/library/genes/6416 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK8 | 5599 | PubTator's text mining | https://conductscience.org/library/genes/5599 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20101022
GET https://conductscience.org/api/papers/v1/20101022/references?page=2